187 740

Cited 0 times in

Is fourth-line chemotherapy routine practice in advanced non-small cell lung cancer?

DC Field Value Language
dc.contributor.authorChoi, YW-
dc.contributor.authorAhn, MS-
dc.contributor.authorJeong, GS-
dc.contributor.authorLee, HW-
dc.contributor.authorJeong, SH-
dc.contributor.authorKang, SY-
dc.contributor.authorPark, JS-
dc.contributor.authorChoi, JH-
dc.contributor.authorLee, SY-
dc.date.accessioned2017-06-05T06:32:48Z-
dc.date.available2017-06-05T06:32:48Z-
dc.date.issued2015-
dc.identifier.issn0169-5002-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/14036-
dc.description.abstractBACKGROUND: Despite advances in palliative chemotherapy, patients with advanced non-small cell lung cancer (NSCLC) eventually experience disease progression during or after completion of first-line chemotherapy, which requires salvage therapy. Second- or third-line therapy in selected patients is recommended in the current guidelines. Although fourth-line therapy is often performed in daily practice in some countries, there are few reports about the clinical benefits of fourth-line therapy.

PATIENTS AND METHODS: A retrospective review was conducted on 383 patients who underwent at least first-line palliative chemotherapy for advanced NSCLC (stage IV or stage IIIB/recurrent disease unsuitable for definitive local therapy). Overall survival (OS) and clinicopathological characteristics were analyzed according to the lines of chemotherapy as well as for all study patients.

RESULTS: The median OS for all patients after the initiation of first-line therapy was 11 months. The median OS for patients who received fourth- or further-line therapy (77 patients) was longer than that of patients who received third- or lesser-line therapy (27 versus 9 months, p<0.0001). In multivariate analysis, fourth- or further-line therapy was independently associated with favorable OS (hazard ratio: 0.44, 95% confidence interval: 0.34-0.57, p<0.0001) along with recurrent disease, female, age <70 years, and ECOG performance status (PS) 0 or 1. Median OS after the start of fourth-line therapy was 9 months. Good PS (ECOG PS 0, 1) at the initiation of fourth-line therapy (10 versus 2 months, p<0.0001) and disease control (10 versus 7 months, p=0.011) after first-line therapy were associated with favorable OS in univariate analysis, while poor PS (ECOG PS ≥2) was an independent prognostic factor for poor outcome (p<0.0001).

CONCLUSION: The present study suggests that advanced NSCLC patients with good PS after progression from third-line therapy could be considered as reasonable candidates for fourth-line therapy in clinical practice.
-
dc.language.isoen-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 andover-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/drug therapy-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/mortality-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/pathology-
dc.subject.MESHDisease Progression-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHLung Neoplasms/drug therapy-
dc.subject.MESHLung Neoplasms/mortality-
dc.subject.MESHLung Neoplasms/pathology-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Metastasis-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHRetreatment-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHRisk Factors-
dc.subject.MESHSurvival Analysis-
dc.subject.MESHTreatment Outcome-
dc.titleIs fourth-line chemotherapy routine practice in advanced non-small cell lung cancer?-
dc.typeArticle-
dc.identifier.pmid25488862-
dc.identifier.urlhttps://linkinghub.elsevier.com/retrieve/pii/S0169-5002(14)00489-9-
dc.contributor.affiliatedAuthor최, 용원-
dc.contributor.affiliatedAuthor안, 미선-
dc.contributor.affiliatedAuthor이, 현우-
dc.contributor.affiliatedAuthor정, 성현-
dc.contributor.affiliatedAuthor강, 석윤-
dc.contributor.affiliatedAuthor박, 준성-
dc.contributor.affiliatedAuthor최, 진혁-
dc.contributor.affiliatedAuthor이, 순영-
dc.type.localJournal Papers-
dc.identifier.doi10.1016/j.lungcan.2014.11.016-
dc.citation.titleLung cancer (Amsterdam, Netherlands)-
dc.citation.volume87-
dc.citation.number2-
dc.citation.date2015-
dc.citation.startPage155-
dc.citation.endPage161-
dc.identifier.bibliographicCitationLung cancer (Amsterdam, Netherlands), 87(2). : 155-161, 2015-
dc.identifier.eissn1872-8332-
dc.relation.journalidJ001695002-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
Journal Papers > School of Medicine / Graduate School of Medicine > Preventive Medicine & Public Health
Files in This Item:
25488862.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse